| 2026-08-06 | Press release | Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-04 | Press release | Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non |
| 2026-07-22 | Press release | Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 |
| 2026-07-20 | Press release | Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies |
| 2026-07-06 | Press release | Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering |
| 2026-07-06 | 8-K | Form 8-K, Item 2.03 |
| 2026-06-30 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-29 | Press release | Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive |
| 2026-06-25 | Press release | Nuvation Bio Announces Proposed Convertible Senior Notes Offering |
| 2026-06-25 | Press release | Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes |
| 2026-05-27 | Press release | Nuvation Bio to Present at the Jefferies Global Healthcare Conference |
| 2026-05-27 | Press release | Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small C |
| 2026-05-27 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-15 | Deck | Investor presentation · May 2026 |
| 2026-05-13 | Press release | Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non |
| 2026-05-06 | Press release | Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Dur |
| 2026-05-05 | Press release | Nuvation Bio to Participate in Upcoming Investor Conferences |
| 2026-05-04 | Press release | Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-04 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-27 | Press release | Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Cli |
| 2026-04-21 | Press release | Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivot |
| 2026-04-21 | Deck | Nuvation Bio Corporate Presentation (April 2026) |
| 2026-04-20 | Press release | Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 |
| 2026-04-10 | Proxy | Definitive proxy statement |
| 2026-04-01 | Press release | Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo |
| 2026-03-26 | Press release | Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1 |
| 2026-03-17 | Press release | Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS |
| 2026-03-02 | Press release | Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-03-02 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-02 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-25 | Press release | Nuvation Bio to Participate in Upcoming Investor Conferences |
| 2026-02-17 | Press release | Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 |
| 2026-02-09 | Press release | Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma |
| 2026-01-13 | Press release | Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2026-01-13 | Press release | Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of |
| 2026-01-12 | Press release | Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Out |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |